Details of the Drug

General Information of Drug (ID: DMETYK5)

Drug Name
Triazolam
Synonyms
Clorazolam; Halcion; Hypnostat; Novidorm; Novodorm; Songar; Triazolamum; Trilam; Apo Triazo; Apotex Brand of Triazolam; Gen Triazolam; Genpharm Brand of Triazolam; Gerard Brand of Triazolam; Pfizer Brand of Triazolam; Triazolam Pfizer Brand; TGAR01H; U 33030; Alti-Triazolam; Apo-Triazo; Gen-Triazolam; Halcion (TN); Halcion (triazolam); Hypam (TN); Novo-Triolam; Triazolamum [INN-Latin]; Trilam (TN); U 33,030; U-33030; U33,030; Apo-Triazo (TN); U-33,030; Triazolam (JAN/USP/INN); Triazolam [USAN:BAN:INN:JAN]; 8-Chloro-6-(2-chlorophenyl)-1-methyl-4H-(1,2,4)triazolo(4,3-a)(1,4)benzodiazepine; 8-Chloro-6-(2-chlorophenyl)-1-methyl-4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepine; 8-Chloro-6-(o-chlorophenyl)-1-methyl-4H-s-triazolo(4,3-a)(1,4)benzodiazepine; 8-Chloro-6-(o-chlorophenyl)-1-methyl-4H-s-triazolo[4,3-a][1,4]benzodiazepine; 8-Chloro-6-[2-chlorophenyl]-1-methyl-4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepine
Indication
Disease Entry ICD 11 Status REF
Insomnia 7A00-7A0Z Approved [1], [2]
Therapeutic Class
Hypnotics and Sedatives
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 0 Molecular Weight (mw) 343.2
Topological Polar Surface Area (xlogp) 2.4
Rotatable Bond Count (rotbonds) 1
Hydrogen Bond Donor Count (hbonddonor) 0
Hydrogen Bond Acceptor Count (hbondacc) 3
ADMET Property
BDDCS Class
Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 1: high solubility and high permeability [3]
Bioavailability
The bioavailability of drug is 44% [4]
Clearance
The drug present in the plasma can be removed from the body at the rate of 3 mL/min/kg [5]
Elimination
2% of drug is excreted from urine in the unchanged form [3]
Half-life
The concentration or amount of drug in body reduced by one-half in 1.5 - 5.5 hours [5]
Metabolism
The drug is metabolized via the hepatic [4]
MRTD
The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 0.0208 micromolar/kg/day [6]
Unbound Fraction
The unbound fraction of drug in plasma is 0.1% [5]
Vd
Fluid volume that would be required to contain the amount of drug present in the body at the same concentration as in the plasma 0.58 L/kg [5]
Water Solubility
The ability of drug to dissolve in water is measured as 0.045 mg/mL [3]
Chemical Identifiers
Formula
C17H12Cl2N4
IUPAC Name
8-chloro-6-(2-chlorophenyl)-1-methyl-4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepine
Canonical SMILES
CC1=NN=C2N1C3=C(C=C(C=C3)Cl)C(=NC2)C4=CC=CC=C4Cl
InChI
InChI=1S/C17H12Cl2N4/c1-10-21-22-16-9-20-17(12-4-2-3-5-14(12)19)13-8-11(18)6-7-15(13)23(10)16/h2-8H,9H2,1H3
InChIKey
JOFWLTCLBGQGBO-UHFFFAOYSA-N
Cross-matching ID
PubChem CID
5556
ChEBI ID
CHEBI:9674
CAS Number
28911-01-5
DrugBank ID
DB00897
TTD ID
D0U3LS
VARIDT ID
DR00865
INTEDE ID
DR1637
ACDINA ID
D00701

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Translocator protein (TSPO) TTPTXIN TSPO_HUMAN Modulator [7]

Drug-Metabolizing Enzyme (DME)
DME Name DME ID UniProt ID MOA REF
Cytochrome P450 3A4 (CYP3A4) DE4LYSA CP3A4_HUMAN Substrate [8]
Cytochrome P450 3A5 (CYP3A5) DEIBDNY CP3A5_HUMAN Substrate [8]
Cytochrome P450 3A7 (CYP3A7) DERD86B CP3A7_HUMAN Substrate [9]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Disease Different from Triazolam (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Sodium bicarbonate DMMU6BJ Minor Altered absorption of Triazolam due to GI dynamics variation caused by Sodium bicarbonate. Acidosis [5C73] [37]
Ivosidenib DM8S6T7 Moderate Increased metabolism of Triazolam caused by Ivosidenib mediated induction of CYP450 enzyme. Acute myeloid leukaemia [2A60] [38]
Arn-509 DMT81LZ Moderate Increased metabolism of Triazolam caused by Arn-509 mediated induction of CYP450 enzyme. Acute myeloid leukaemia [2A60] [39]
Oliceridine DM6MDCF Major Additive CNS depression effects by the combination of Triazolam and Oliceridine. Acute pain [MG31] [40]
Emapalumab DMZG5WL Moderate Altered metabolism of Triazolam due to Emapalumab alters the formation of CYP450 enzymes. Adaptive immunity immunodeficiency [4A01] [39]
Siltuximab DMGEATB Moderate Altered metabolism of Triazolam due to Siltuximab alters the formation of CYP450 enzymes. Anemia [3A00-3A9Z] [39]
Dronedarone DMA8FS5 Moderate Decreased metabolism of Triazolam caused by Dronedarone mediated inhibition of CYP450 enzyme. Angina pectoris [BA40] [41]
Posaconazole DMUL5EW Major Decreased metabolism of Triazolam caused by Posaconazole mediated inhibition of CYP450 enzyme. Aspergillosis [1F20] [42]
Dalfopristin DM4LTKV Moderate Decreased metabolism of Triazolam caused by Dalfopristin mediated inhibition of CYP450 enzyme. Bacterial infection [1A00-1C4Z] [43]
Clarithromycin DM4M1SG Moderate Decreased metabolism of Triazolam caused by Clarithromycin mediated inhibition of CYP450 enzyme. Bacterial infection [1A00-1C4Z] [42]
Troleandomycin DMUZNIG Moderate Decreased metabolism of Triazolam caused by Troleandomycin mediated inhibition of CYP450 enzyme. Bacterial infection [1A00-1C4Z] [44]
Telithromycin DMZ4P3A Major Decreased metabolism of Triazolam caused by Telithromycin mediated inhibition of CYP450 enzyme. Bacterial infection [1A00-1C4Z] [45]
Erdafitinib DMI782S Moderate Increased metabolism of Triazolam caused by Erdafitinib mediated induction of CYP450 enzyme. Bladder cancer [2C94] [46]
Lapatinib DM3BH1Y Moderate Decreased metabolism of Triazolam caused by Lapatinib mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [47]
Tucatinib DMBESUA Major Decreased metabolism of Triazolam caused by Tucatinib mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [48]
Palbociclib DMD7L94 Moderate Decreased metabolism of Triazolam caused by Palbociclib mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [49]
Dihydrocodeine DMB0FWL Major Additive CNS depression effects by the combination of Triazolam and Dihydrocodeine. Chronic pain [MG30] [50]
Remifentanil DMZTXCH Major Additive CNS depression effects by the combination of Triazolam and Remifentanil. Corneal disease [9A76-9A78] [40]
Lumacaftor DMCLWDJ Major Increased metabolism of Triazolam caused by Lumacaftor mediated induction of CYP450 enzyme. Cystic fibrosis [CA25] [42]
Ivacaftor DMZC1HS Moderate Decreased metabolism of Triazolam caused by Ivacaftor mediated inhibition of CYP450 enzyme. Cystic fibrosis [CA25] [51]
Ethanol DMDRQZU Moderate Additive CNS depression effects by the combination of Triazolam and Ethanol. Cystitis [GC00] [52]
Nefazodone DM4ZS8M Major Decreased metabolism of Triazolam caused by Nefazodone mediated inhibition of CYP450 enzyme. Depression [6A70-6A7Z] [53]
Esketamine DMVU687 Moderate Additive CNS depression effects by the combination of Triazolam and Esketamine. Depression [6A70-6A7Z] [42]
SODIUM CITRATE DMHPD2Y Minor Altered absorption of Triazolam due to GI dynamics variation caused by SODIUM CITRATE. Discovery agent [N.A.] [37]
Cenobamate DMGOVHA Moderate Increased metabolism of Triazolam caused by Cenobamate mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [54]
Fosphenytoin DMOX3LB Moderate Increased metabolism of Triazolam caused by Fosphenytoin mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [55]
Tazemetostat DMWP1BH Moderate Increased metabolism of Triazolam caused by Tazemetostat mediated induction of CYP450 enzyme. Follicular lymphoma [2A80] [56]
Itraconazole DMCR1MV Major Decreased metabolism of Triazolam caused by Itraconazole mediated inhibition of CYP450 enzyme. Fungal infection [1F29-1F2F] [48]
Miconazole DMPMYE8 Moderate Decreased metabolism of Triazolam caused by Miconazole mediated inhibition of CYP450 enzyme. Fungal infection [1F29-1F2F] [48]
Ketoconazole DMPZI3Q Major Decreased metabolism of Triazolam caused by Ketoconazole mediated inhibition of CYP450 enzyme. Fungal infection [1F29-1F2F] [48]
Boceprevir DMBSHMF Major Decreased metabolism of Triazolam caused by Boceprevir mediated inhibition of CYP450 enzyme. Hepatitis virus infection [1E50-1E51] [57]
Simeprevir DMLUA9D Moderate Decreased metabolism of Triazolam caused by Simeprevir mediated inhibition of CYP450 enzyme. Hepatitis virus infection [1E50-1E51] [58]
Telaprevir DMMRV29 Major Decreased metabolism of Triazolam caused by Telaprevir mediated inhibition of CYP450 enzyme. Hepatitis virus infection [1E50-1E51] [57]
Isoniazid DM5JVS3 Moderate Decreased metabolism of Triazolam caused by Isoniazid mediated inhibition of CYP450 enzyme. HIV-infected patients with tuberculosis [1B10-1B14] [59]
Rifampin DMA8J1G Minor Increased metabolism of Triazolam caused by Rifampin mediated induction of CYP450 enzyme. HIV-infected patients with tuberculosis [1B10-1B14] [60]
Rifapentine DMCHV4I Moderate Increased metabolism of Triazolam caused by Rifapentine mediated induction of CYP450 enzyme. HIV-infected patients with tuberculosis [1B10-1B14] [61]
Fosamprenavir DM4W9B3 Major Decreased metabolism of Triazolam caused by Fosamprenavir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [62]
Cobicistat DM6L4H2 Major Decreased metabolism of Triazolam caused by Cobicistat mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [48]
Saquinavir DMG814N Major Decreased metabolism of Triazolam caused by Saquinavir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [62]
Etravirine DMGV8QU Moderate Increased metabolism of Triazolam caused by Etravirine mediated induction of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [63]
Didanosine DMI2QPE Minor Altered absorption of Triazolam due to GI dynamics variation caused by Didanosine. Human immunodeficiency virus disease [1C60-1C62] [37]
Darunavir DMN3GCH Major Decreased metabolism of Triazolam caused by Darunavir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [62]
Atazanavir DMSYRBX Major Decreased metabolism of Triazolam caused by Atazanavir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [62]
Probenecid DMMFWOJ Minor Decreased metabolism of Triazolam caused by Probenecid. Inborn purine/pyrimidine/nucleotide metabolism error [5C55] [64]
Lesinurad DMUR64T Moderate Increased metabolism of Triazolam caused by Lesinurad mediated induction of CYP450 enzyme. Inborn purine/pyrimidine/nucleotide metabolism error [5C55] [65]
Berotralstat DMWA2DZ Moderate Decreased metabolism of Triazolam caused by Berotralstat mediated inhibition of CYP450 enzyme. Innate/adaptive immunodeficiency [4A00] [66]
Crizotinib DM4F29C Moderate Decreased metabolism of Triazolam caused by Crizotinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [67]
Brigatinib DM7W94S Moderate Increased metabolism of Triazolam caused by Brigatinib mediated induction of CYP450 enzyme. Lung cancer [2C25] [68]
Ceritinib DMB920Z Major Decreased metabolism of Triazolam caused by Ceritinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [48]
PF-06463922 DMKM7EW Moderate Increased metabolism of Triazolam caused by PF-06463922 mediated induction of CYP450 enzyme. Lung cancer [2C25] [69]
Osimertinib DMRJLAT Moderate Increased metabolism of Triazolam caused by Osimertinib mediated induction of CYP450 enzyme. Lung cancer [2C25] [39]
Selpercatinib DMZR15V Moderate Decreased metabolism of Triazolam caused by Selpercatinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [39]
Idelalisib DM602WT Major Decreased metabolism of Triazolam caused by Idelalisib mediated inhibition of CYP450 enzyme. Mature B-cell leukaemia [2A82] [48]
IPI-145 DMWA24P Moderate Decreased metabolism of Triazolam caused by IPI-145 mediated inhibition of CYP450 enzyme. Mature B-cell leukaemia [2A82] [70]
LGX818 DMNQXV8 Moderate Increased metabolism of Triazolam caused by LGX818 mediated induction of CYP450 enzyme. Melanoma [2C30] [71]
Allopregnanolone DMNLHAC Moderate Additive CNS depression effects by the combination of Triazolam and Allopregnanolone. Mental/behavioural/neurodevelopmental disorder [6E20-6E8Z] [72]
Lasmiditan DMXLVDT Moderate Additive CNS depression effects by the combination of Triazolam and Lasmiditan. Migraine [8A80] [73]
Exjade DMHPRWG Moderate Decreased metabolism of Triazolam caused by Exjade mediated inhibition of CYP450 enzyme. Mineral absorption/transport disorder [5C64] [74]
Flibanserin DM70DTN Moderate Additive CNS depression effects by the combination of Triazolam and Flibanserin. Mood disorder [6A60-6E23] [75]
Thalidomide DM70BU5 Moderate Additive CNS depression effects by the combination of Triazolam and Thalidomide. Multiple myeloma [2A83] [76]
Fedratinib DM4ZBK6 Moderate Decreased metabolism of Triazolam caused by Fedratinib mediated inhibition of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [39]
Nilotinib DM7HXWT Moderate Decreased metabolism of Triazolam caused by Nilotinib mediated inhibition of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [77]
Dasatinib DMJV2EK Moderate Decreased metabolism of Triazolam caused by Dasatinib mediated inhibition of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [78]
Teduglutide DMYOAKS Moderate Altered absorption of Triazolam caused by Teduglutide. Neonatal malabsorption syndrome [KB89] [79]
Entrectinib DMMPTLH Moderate Decreased metabolism of Triazolam caused by Entrectinib mediated inhibition of CYP450 enzyme. Non-small cell lung cancer [2C25] [80]
Levomethadyl Acetate DM06HG5 Major Additive CNS depression effects by the combination of Triazolam and Levomethadyl Acetate. Opioid use disorder [6C43] [50]
Apraclonidine DMO4PVE Moderate Additive CNS depression effects by the combination of Triazolam and Apraclonidine. Optic nerve disorder [9C40] [81]
Olaparib DM8QB1D Moderate Decreased metabolism of Triazolam caused by Olaparib mediated inhibition of CYP450 enzyme. Ovarian cancer [2C73] [42]
Rucaparib DM9PVX8 Moderate Decreased metabolism of Triazolam caused by Rucaparib mediated inhibition of CYP450 enzyme. Ovarian cancer [2C73] [82]
Oxymorphone DM65AGJ Major Additive CNS depression effects by the combination of Triazolam and Oxymorphone. Pain [MG30-MG3Z] [40]
Dezocine DMJDB0Y Major Additive CNS depression effects by the combination of Triazolam and Dezocine. Pain [MG30-MG3Z] [40]
Buprenorphine DMPRI8G Major Additive CNS depression effects by the combination of Triazolam and Buprenorphine. Pain [MG30-MG3Z] [83]
Hydrocodone DMQ2JO5 Major Additive CNS depression effects by the combination of Triazolam and Hydrocodone. Pain [MG30-MG3Z] [40]
Abametapir DM2RX0I Moderate Decreased metabolism of Triazolam caused by Abametapir mediated inhibition of CYP450 enzyme. Pediculosis [1G00] [84]
Lonafarnib DMGM2Z6 Major Decreased metabolism of Triazolam caused by Lonafarnib mediated inhibition of CYP450 enzyme. Premature ageing appearance [LD2B] [48]
Enzalutamide DMGL19D Moderate Increased metabolism of Triazolam caused by Enzalutamide mediated induction of CYP450 enzyme. Prostate cancer [2C82] [85]
Ustekinumab DMHTYK3 Moderate Altered metabolism of Triazolam due to Ustekinumab alters the formation of CYP450 enzymes. Psoriasis [EA90] [39]
Temsirolimus DMS104F Moderate Increased plasma concentrations of Triazolam and Temsirolimus due to competitive inhibition of the same metabolic pathway. Renal cell carcinoma [2C90] [86]
Tocilizumab DM7J6OR Moderate Altered metabolism of Triazolam due to Tocilizumab alters the formation of CYP450 enzymes. Rheumatoid arthritis [FA20] [39]
Canakinumab DM8HLO5 Moderate Altered metabolism of Triazolam due to Canakinumab alters the formation of CYP450 enzymes. Rheumatoid arthritis [FA20] [39]
Rilonacept DMGLUQS Moderate Altered metabolism of Triazolam due to Rilonacept alters the formation of CYP450 enzymes. Rheumatoid arthritis [FA20] [39]
Golimumab DMHZV7X Moderate Altered metabolism of Triazolam due to Golimumab alters the formation of CYP450 enzymes. Rheumatoid arthritis [FA20] [39]
Sarilumab DMOGNXY Moderate Altered metabolism of Triazolam due to Sarilumab alters the formation of CYP450 enzymes. Rheumatoid arthritis [FA20] [39]
Voxelotor DMCS6M5 Moderate Decreased metabolism of Triazolam caused by Voxelotor mediated inhibition of CYP450 enzyme. Sickle-cell disorder [3A51] [87]
Telotristat ethyl DMDIYFZ Moderate Increased metabolism of Triazolam caused by Telotristat ethyl mediated induction of CYP450 enzyme. Small intestine developmental anomaly [DA90] [39]
Larotrectinib DM26CQR Moderate Decreased metabolism of Triazolam caused by Larotrectinib mediated inhibition of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [42]
Armodafinil DMGB035 Moderate Increased metabolism of Triazolam caused by Armodafinil mediated induction of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [88]
LEE011 DMMX75K Moderate Decreased metabolism of Triazolam caused by LEE011 mediated inhibition of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [89]
Fostamatinib DM6AUHV Moderate Decreased metabolism of Triazolam caused by Fostamatinib mediated inhibition of CYP450 enzyme. Thrombocytopenia [3B64] [90]
Brilinta DMBR01X Moderate Decreased metabolism of Triazolam caused by Brilinta mediated inhibition of CYP450 enzyme. Thrombosis [DB61-GB90] [39]
Amiodarone DMUTEX3 Minor Potentiate the pharmacologic effects by the combination of Triazolam and Amiodarone. Ventricular tachyarrhythmia [BC71] [91]
⏷ Show the Full List of 91 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG
DIG Name DIG ID PubChem CID Functional Classification
Docusate sodium E00563 23673837 Surfactant
FD&C blue no. 1 E00263 19700 Colorant
FD&C blue no. 2 E00446 2723854 Colorant
Sodium benzoate E00432 517055 Antimicrobial preservative; lubricant
Beta-D-lactose E00099 6134 Diluent; Dry powder inhaler carrier; Lyophilization aid
Magnesium stearate E00208 11177 lubricant
Silicon dioxide E00670 Not Available Anticaking agent; Opacifying agent; Viscosity-controlling agent
⏷ Show the Full List of 7 Pharmaceutical Excipients of This Drug
Pharmaceutical Formulation
Formulation Name Drug Dosage Dosage Form Route
Triazolam 0.25 mg tablet 0.25 mg Oral Tablet Oral
Triazolam 0.125 mg tablet 0.125 mg Oral Tablet Oral
Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7313).
2 What every dentist should know about the "z-sedatives". J Mass Dent Soc. 2007 Fall;56(3):44-5.
3 BDDCS applied to over 900 drugs
4 FDA approval: ado-trastuzumab emtansine for the treatment of patients with HER2-positive metastatic breast cancer. Clin Cancer Res. 2014 Sep 1;20(17):4436-41.
5 Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
6 Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
7 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
8 In vitro metabolism of midazolam, triazolam, nifedipine, and testosterone by human liver microsomes and recombinant cytochromes p450: role of cyp3a4 and cyp3a5. Drug Metab Dispos. 2003 Jul;31(7):938-44.
9 Drug Interactions Flockhart Table
10 Expression levels and activation of a PXR variant are directly related to drug resistance in osteosarcoma cell lines. Cancer. 2007 Mar 1;109(5):957-65.
11 Contribution of human hepatic cytochrome P450 isoforms to regioselective hydroxylation of steroid hormones. Xenobiotica. 1998 Jun;28(6):539-47.
12 Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6. J Pharmacol Exp Ther. 2004 Sep;310(3):1062-75.
13 Isoform-specific regulation of cytochromes P450 expression by estradiol and progesterone. Drug Metab Dispos. 2013 Feb;41(2):263-9.
14 Metabolic interactions between acetaminophen (paracetamol) and two flavonoids, luteolin and quercetin, through in-vitro inhibition studies. J Pharm Pharmacol. 2017 Dec;69(12):1762-1772.
15 Potent mechanism-based inhibition of CYP3A4 by imatinib explains its liability to interact with CYP3A4 substrates. Br J Pharmacol. 2012 Apr;165(8):2787-98.
16 Effects of morin on the pharmacokinetics of etoposide in rats. Biopharm Drug Dispos. 2007 Apr;28(3):151-6.
17 The metabolism of zidovudine by human liver microsomes in vitro: formation of 3'-amino-3'-deoxythymidine. Biochem Pharmacol. 1994 Jul 19;48(2):267-76.
18 Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
19 Drug related genetic polymorphisms affecting adverse reactions to methotrexate, vinblastine, doxorubicin and cisplatin in patients with urothelial cancer. J Urol. 2008 Dec;180(6):2389-95.
20 Human prostate CYP3A5: identification of a unique 5'-untranslated sequence and characterization of purified recombinant protein. Biochem Biophys Res Commun. 1999 Jul 14;260(3):676-81.
21 Polymorphisms in cytochrome P4503A5 (CYP3A5) may be associated with race and tumor characteristics, but not metabolism and side effects of tamoxifen in breast cancer patients. Cancer Lett. 2005 Jan 10;217(1):61-72.
22 Induction of hepatic CYP2E1 by a subtoxic dose of acetaminophen in rats: increase in dichloromethane metabolism and carboxyhemoglobin elevation. Drug Metab Dispos. 2007 Oct;35(10):1754-8.
23 Urinary 6 beta-hydroxycortisol excretion in rheumatoid arthritis. Br J Rheumatol. 1997 Jan;36(1):54-8.
24 Clinical pharmacokinetics of imatinib. Clin Pharmacokinet. 2005;44(9):879-94.
25 Kinetics and regulation of cytochrome P450-mediated etoposide metabolism. Drug Metab Dispos. 2004 Sep;32(9):993-1000.
26 Differential mechanism-based inhibition of CYP3A4 and CYP3A5 by verapamil. Drug Metab Dispos. 2005 May;33(5):664-71.
27 The role of cytochrome P450 3A (CYP3A) isoform(s) in oxidative metabolism of testosterone and benzphetamine in human adult and fetal liver. J Steroid Biochem Mol Biol. 1993 Jan;44(1):61-7.
28 Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
29 Prediction of cytochrome P450 3A inhibition by verapamil enantiomers and their metabolites. Drug Metab Dispos. 2004 Feb;32(2):259-66.
30 The role of human cytochrome P450 enzymes in the formation of 2-hydroxymetronidazole: CYP2A6 is the high affinity (low Km) catalyst. Drug Metab Dispos. 2013 Sep;41(9):1686-94.
31 Translocator protein (18 kDa) mediates the pro-growth effects of diazepam on Ehrlich tumor cells in vivo. Eur J Pharmacol. 2010 Jan 25;626(2-3):131-8.
32 Comparison of five benzodiazepine-receptor agonists on buprenorphine-induced mu-opioid receptor regulation. J Pharmacol Sci. 2009 May;110(1):36-46.
33 Effects of the combination of metyrapone and oxazepam on cocaine and food self-administration in rats. Pharmacol Biochem Behav. 2008 Nov;91(1):181-9.
34 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2879).
35 Effects of benzodiazepines and non-benzodiazepine compounds on the GABA-induced response in frog isolated sensory neurones. Br J Pharmacol. 1989 Nov;98(3):735-40.
36 New hypnotics: perspectives from sleep physiology. Vertex. 2007 Jul-Aug;18(74):294-9.
37 Chun AH, Carrigan PJ, Hoffman DJ, Kershner RP, Stuart JD "Effect of antacids on absorption of clorazepate." Clin Pharmacol Ther 22 (1977): 329-35. [PMID: 19188]
38 Product Information. Tibsovo (ivosidenib). Agios Pharmaceuticals, Cambridge, MA.
39 Cerner Multum, Inc. "UK Summary of Product Characteristics.".
40 US Food and Drug Administration "FDA warns about serious risks and death when combining opioid pain or cough medicines with benzodiazepines requires its strongest warning.".
41 Product Information. Multaq (dronedarone). sanofi-aventis , Bridgewater, NJ.
42 Cerner Multum, Inc. "Australian Product Information.".
43 Product Information. Synercid (dalfopristin-quinupristin) Rhone-Poulenc Rorer, Collegeville, PA.
44 Amsden GW "Macrolides versus azalides: a drug interaction update." Ann Pharmacother 29 (1995): 906-17. [PMID: 8547740]
45 Product Information. Ketek (telithromycin). Aventis Pharmaceuticals, Bridgewater, NJ.
46 Product Information. Balversa (erdafitinib). Janssen Products, LP, Horsham, PA.
47 Product Information. Tykerb (lapatinib). Novartis Pharmaceuticals, East Hanover, NJ.
48 Ahonen J, Olkkola KT, Neuvonen PJ "Effect of itraconazole and terbinafine on the pharmacokinetics and pharmacodynamics of midazolam in healthy volunteers." Br J Clin Pharmacol 40 (1995): 270-2. [PMID: 8527290]
49 Product Information. Ibrance (palbociclib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
50 US Food and Drug Administration "FDA warns about serious risks and death when combining opioid pain or cough medicines with benzodiazepines requires its strongest warning.".
51 Product Information. Kalydeco (ivacaftor). Vertex Pharmaceuticals, Cambridge, MA.
52 Divoll M, Greenblatt DJ, Lacasse Y, Shader RI "Benzodiazepine overdosage: plasma concentrations and clinical outcome." Psychopharmacology (Berl) 73 (1981): 381-3. [PMID: 6789361]
53 Barbhaiya RH, Shukla UA, Kroboth PD, Greene DS "Coadministration of nefazodone and benzodiazepines: 2. a pharmacokinetic interaction study with triazolam." J Clin Psychopharmacol 15 (1995): 320-6. [PMID: 8830062]
54 Product Information. Xcopri (cenobamate). SK Life Science, Inc., Paramus, NJ.
55 Backman JT, Olkkola KT, Ojala M, Laaksovirta H, Neuvonen PJ "Concentrations and effects of oral midazolam are greatly reduced in patients treated with carbamazepine or phenytoin." Epilepsia 37 (1996): 253-7. [PMID: 8598183]
56 Product Information. Tazverik (tazemetostat). Epizyme, Inc, Cambridge, MA.
57 Product Information. Incivek (telaprevir). Vertex Pharmaceuticals, Cambridge, MA.
58 Product Information. Olysio (simeprevir). Janssen Pharmaceuticals, Titusville, NJ.
59 Ochs HR, Greenblatt DJ, Knuchel M "Differential effect of isoniazid on triazolam oxidation and oxazepam conjugation." Br J Clin Pharmacol 16 (1983): 743-6. [PMID: 6140941]
60 Ochs HR, Greenblatt DJ, Roberts GM, Dengler HJ "Diazepam interaction with antituberculosis drugs." Clin Pharmacol Ther 29 (1981): 671-8. [PMID: 7214796]
61 Product Information. Priftin (rifapentine). Hoechst Marion-Roussel Inc, Kansas City, MO.
62 Barry M, Mulcahy F, Merry C, Gibbons S, Back D "Pharmacokinetics and potential interactions amongst antiretroviral agents used to treat patients with HIV infection." Clin Pharmacokinet 36 (1999): 289-304. [PMID: 10320951]
63 Product Information. Intelence (etravirine). Ortho Biotech Inc, Bridgewater, NJ.
64 Abernethy DR, Greenblatt DJ, Ameer B, Shader RI "Probenecid impairment of acetaminophen and lorazepam clearance: direct inhibition of ether glucuronide formation." J Pharmacol Exp Ther 234 (1985): 345-9. [PMID: 4020675]
65 Product Information. Zurampic (lesinurad). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
66 Product Information. Orladeyo (berotralstat). BioCryst Pharmaceuticals Inc, Durham, NC.
67 Product Information. Xalkori (crizotinib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
68 Product Information. Alunbrig (brigatinib). Ariad Pharmaceuticals Inc, Cambridge, MA.
69 Product Information. Lorbrena (lorlatinib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
70 Product Information. Copiktra (duvelisib). Verastem, Inc., Needham, MA.
71 Product Information. Braftovi (encorafenib). Array BioPharma Inc., Boulder, CO.
72 Product Information. Zulresso (brexanolone). Sage Therapeutics, Inc., Cambridge, MA.
73 Product Information. Reyvow (lasmiditan). Lilly, Eli and Company, Indianapolis, IN.
74 Product Information. Exjade (deferasirox). Novartis Pharmaceuticals, East Hanover, NJ.
75 Product Information. Addyi (flibanserin). Sprout Pharmaceuticals, Raleigh, NC.
76 Product Information. Thalomid (thalidomide). Celgene Corporation, Warren, NJ.
77 Product Information. Tasigna (nilotinib). Novartis Pharmaceuticals, East Hanover, NJ.
78 Product Information. Sprycel (dasatinib). Bristol-Myers Squibb, Princeton, NJ.
79 Product Information. Gattex (teduglutide). NPS Pharmaceuticals, Bedminster, NJ.
80 Product Information. Rozlytrek (entrectinib). Genentech, South San Francisco, CA.
81 Product Information. Alphagan (brimonidine ophthalmic). Allergan Inc, Irvine, CA.
82 EMA. European Medicines Agency. European Union "EMA - List of medicines under additional monitoring.".
83 Sekar M, Mimpriss TJ "Buprenorphine, benzodiazepines and prolonged respiratory depression." Anaesthesia 42 (1987): 567-8. [PMID: 3592200]
84 Product Information. Xeglyze (abametapir topical). Dr. Reddy's Laboratories Inc, Upper Saddle River, NJ.
85 Benoist G, van Oort I, et al "Drug-drug interaction potential in men treated with enzalutamide: Mind the gap." Br J Clin Pharmacol 0 (2017): epub. [PMID: 28881501]
86 Product Information. Prograf (tacrolimus). Fujisawa, Deerfield, IL.
87 Product Information. Oxbryta (voxelotor). Global Blood Therapeutics, Inc., South San Francisco, CA.
88 Product Information. Nuvigil (armodafinil). Cephalon Inc, West Chester, PA.
89 DSouza DL, Levasseur LM, Nezamis J, Robbins DK, Simms L, Koch KM "Effect of alosetron on the pharmacokinetics of alprazolam." J Clin Pharmacol 41 (2001): 452-4. [PMID: 11304902]
90 Product Information. Tavalisse (fostamatinib). Rigel Pharmaceuticals, South San Francisco, CA.
91 Kerin NZ, Aragon E, Faitel K, Frumin H, Rubenfire M "Long-term efficacy and toxicity of high- and low-dose amiodarone regimens." J Clin Pharmacol 29 (1989): 418-23. [PMID: 2661600]